Sage Group's new client, Notogen, is a US registered company focused on a regenerative therapeutic, designated NTG-101, for treating chronic back and neck pain caused by degenerating spinal discs (eg Degenerative Disc Disease, DDD). NTG-101 is available for licensing, strategic partnering or acquisition. NTG-101 is protein-based biologic designed to mediate the progression of spinal disc degeneration disease (DDD) and induce a restorative effect. NTG-101 is an intradiscal mol

PETACH TIKVA, Israel, March 11, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced the successful completion of enrollment in the SHIELD II Phase 3 trial for D-PLEX100 for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery. This milestone follows recommendation by the independent Data Safety Monitoring Board (“DSMB”),